Business Context and Reporting Period
Kura Oncology, Inc. filed a Form 8-K Current Report on March 12, 2018. The filing reports the entry into a Material Definitive Agreement regarding the company's equity financing capabilities.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial data points relate to capital raising:
- Maximum Aggregate Offering Price: Increased from $100.0 million to $160.0 million.
- Additional Shares Authorized: $60.0 million worth of common stock.
- Amount Sold to Date: Approximately $59.3 million of common stock sold through the sales agent.
- Commission Rate: Up to 3.0% of gross sales proceeds paid to the sales agent.
Material Changes
On March 12, 2018, the Company entered into an Amended and Restated Sales Agreement with Cowen and Company, LLC. The material change is the expansion of the "at-the-market" offering program, increasing the total capacity to sell shares by $60.0 million. The filing notes that approximately $59.3 million had already been sold under the terms of this amended agreement as of the filing date.
Outlook, Risks, and Management Commentary
Management Commentary: The Company retains sole discretion over the timing and amount of any sales. It is not obligated to sell any shares under the agreement. Sales may be conducted via ordinary broker transactions, block transactions, or other methods deemed appropriate by the Company.
Risks and Contingencies: The offering will terminate upon the sale of all shares or the termination of the agreement. The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the total number of shares sold to date against the $59.3 million gross proceeds figure.
- Review the full text of the Amended and Restated Sales Agreement (Exhibit 10.1) for specific termination clauses and indemnification details.
- Confirm the current share price to estimate the remaining number of shares available for sale under the $160.0 million cap.
- Check subsequent filings for updates on the utilization of the remaining $100.7 million capacity.